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National data on patient characteristics, treatment, and outcomes of critically ill coro-
navirus disease 2019 (COVID-19) solid organ transplant (SOT) patients are limited. We 
analyzed data from a multicenter cohort study of adults with laboratory-confirmed 
COVID-19 admitted to intensive care units (ICUs) at 68 hospitals across the United 
States from March 4 to May 8, 2020. From 4153 patients, we created a propensity 
score matched cohort of 386 patients, including 98 SOT patients and 288 non-SOT 
patients. We used a binomial generalized linear model (log-binomial model) to examine 
the association of SOT status with death and other clinical outcomes. Among the 386 
patients, the median age was 60 years, 72% were male, and 41% were black. Death 
within 28 days of ICU admission was similar in SOT and non-SOT patients (40% and 
43%, respectively; relative risk [RR] 0.92; 95% confidence interval [CI]: 0.70-1.22). 
Other outcomes and requirement for organ support including receipt of mechanical 
ventilation, development of acute respiratory distress syndrome, and receipt of vaso-
pressors were also similar between groups. There was a trend toward higher risk of 
acute kidney injury requiring renal replacement therapy in SOT vs. non-SOT patients 
(37% vs. 27%; RR [95% CI]: 1.34 [0.97-1.85]). Death and organ support requirement 
were similar between SOT and non-SOT critically ill patients with COVID-19.
K E Y W O R D S
clinical research/practice, complication: infectious, infection and infectious agents - viral, 
infectious disease, kidney transplantation/nephrology, organ transplantation in general, patient 
survival
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1  |  INTRODUC TION
Since December 2019, severe acute respiratory syndrome coro-
navirus 2 (SARS-CoV-2) has spread from Wuhan, China to the rest 
of the world, leading to more than 20 million confirmed cases of 
coronavirus disease 2019 (COVID-19) with more than 738,000 
deaths as of August 11th, 2020.1 The spectrum of clinical dis-
ease from COVID-19 varies from a mild febrile illness to criti-
cal illness, including acute respiratory distress syndrome (ARDS) 
and multiorgan failure, which are associated with high morbidity 
and mortality. Identified risk factors for adverse outcomes from 
COVID-19 include older age, obesity, male sex, and comorbid 
conditions, including diabetes mellitus, hypertension, cardiovas-
cular disease, chronic kidney disease, chronic lung disease, and 
malignancy.2-7
Solid organ transplant (SOT) patients are considered high risk 
for complications from COVID-19 because of their immunosup-
pressed status.8,9 They are more susceptible to infections with 
ribonucleic acid respiratory viruses in general and have a higher 
risk of complications such as bacterial and fungal superinfec-
tion.10 However, because the manifestations of severe COVID-
19, including ARDS and organ dysfunction, may be propagated by 
a proinflammatory state due to cytokine release syndrome,11,12 
immunosuppressive therapy could potentially mitigate some of 
these effects and thereby help prevent severe complications in 
SOT patients.
Current data on the clinical course of COVID-19 in immu-
nocompromised patients are limited predominantly to case 
reports and single-center studies. Among hospitalized SOT 
patients with COVID-19 in New York City, acute mortality 
rates varied between 13%-29%.8,13-15 A similar case fatality 
rate of 20%-28% was reported in hospitalized SOT recip-
ient cohorts from Italy, Spain, the United Kingdom, and the 
Netherlands.9,16-18 A cohort study from Switzerland that in-
cluded 20 hospitalized SOT patients reported a lower mortal-
ity rate of 10%, which was similar to the mortality observed 
in the general population with COVID-19.19 Small case series 
from the United States have also reported similar mortality 
rates in SOT patients with COVID-19 that have been observed 
in the general population.20-23 In addition, there is no data 
available for outcomes of COVID-19 infected SOT patients ad-
mitted in intensive care units. Our paper is aimed to address 
this knowledge gap.
Previously published studies focusing on SOT patients and 
COVID-19 lack comparison with a control group to ascertain their 
risk as compared to the general population.8,9,13-18 To address this 
knowledge gap, we compared outcomes in SOT versus non-SOT pa-
tients with COVID-19 who were admitted to intensive care units 
(ICUs) throughout the United States, using data from a multicenter 
cohort study. We hypothesized that SOT patients would have sim-
ilar risk of death and organ support requirement compared to non-
SOT patients.
2  |  MATERIAL S AND METHODS
2.1  |  Study design and oversight
We used data from the Study of the Treatment and Outcomes in 
critically ill Patients with COVID-19 (STOP-COVID). STOP-COVID is 
a multicenter cohort study that enrolled adults with COVID-19 ad-
mitted to participating ICUs at 68 hospitals across the United States. 
The study was approved by the institutional review board at each 
participating site with a waiver of informed consent and registered 
on ClinicalTrials.gov (NCT04343898).
2.2  |  Study sites and patient population
We included consecutive adult patients (≥18 years old) with lab-
oratory-confirmed COVID-19 (detected by nasopharyngeal or 
oropharyngeal swab) admitted to a participating ICU for illness 
related to COVID-19 between March 4 and May 8, 2020. We fol-
lowed patients until the first of hospital discharge, death, or June 
5, 2020 – the date on which the database for the current analysis 
was locked. A complete list of participating sites is shown in Table 
S1.
2.3  |  Data collection
We collected detailed information about demographics, coexist-
ing conditions, home medications (including immunosuppressive 
medications), symptoms prior to ICU admission, vital signs on ICU 
admission, and longitudinal data on laboratory values, physiologic 
parameters, medications, treatments, and organ support in the first 
14 days following ICU admission. Definitions of baseline characteris-
tics, comorbidities, treatments, and outcomes are shown in Table S2. 
A detailed description of the data collection and validation process 
has been previously published.24
2.4  |  Exposure variable
The primary exposure was SOT at baseline.
2.5  |  Clinical outcomes assessment
The primary outcome was death within 28 days of ICU admission. 
We also assessed the following secondary outcomes: ICU length of 
stay, defined as the time between ICU admission until death, dis-
charge from the ICU, or end of follow-up (if still in the ICU at the 
end of follow-up); receipt and duration of invasive mechanical ven-
tilation; receipt and duration of extracorporeal membrane oxygena-
tion (ECMO, including veno-venous ECMO, veno-arterial ECMO and 
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veno-arterio-venous ECMO); acute kidney injury (AKI) requiring 
renal replacement therapy (RRT) and the number of days of RRT; 
ARDS, ascertained by manual chart review; secondary infection, de-
fined as a suspected or confirmed new infection other than COVID-
19 that developed after admission to the ICU based on microbiology 
cultures or strong clinical suspicion; thromboembolic event, includ-
ing deep venous thrombosis, pulmonary embolism, stroke, or other 
thromboembolic event; receipt of vasopressors and the number of 
days on vasopressor therapy.
2.6  |  Statistical analysis
We summarized baseline patient characteristics according to SOT 
status and presented them as count and percentage for categorical 
variables and median and interquartile range (IQR) for continuous 
variables.
We used a propensity score to account for differences in clini-
cal and demographic characteristics of SOT and non-SOT patients. 
We identified variables associated with SOT status using logistic 
regression and used them to calculate propensity scores. We used 
STATA’s “psmatch2” command suite to generate the propensity 
score-matched cohort by 1-to-4 nearest neighbor matching with 
replacement. The following variables were included in the logis-
tic regression model to create the propensity score: age; gender; 
race; ethnicity; body mass index; comorbidities – diabetes melli-
tus, hypertension, coronary artery disease (includes any history 
of angina, myocardial infarction, or coronary artery bypass graft 
surgery), congestive heart failure (includes both heart failure with 
preserved and reduced ejection fraction), atrial fibrillation/flut-
ter, chronic obstructive pulmonary disease, asthma, other lung 
disease, chronic kidney disease (defined as a baseline estimated 
glomerular filtration rate [eGFR]< 60 mL/min/1.73m2 on at least 
2 consecutive occasions at least 12 weeks apart prior to hospital 
admission or per medical history), chronic liver disease (includes 
cirrhosis, alcohol related liver disease, nonalcoholic fatty liver 
disease, autoimmune hepatitis, hepatitis B or hepatitis C, primary 
biliary cirrhosis), active malignancy (defined as any malignancy, 
other than nonmelanoma skin cancer, treated in the prior year), 
human immunodeficiency virus (HIV)/acquired immunodeficiency 
syndrome (AIDS), smoking status (nonsmoker/current/former 
smoker/unknown); and medication use prior to hospital admission 
(renin-angiotensin-aldosterone system inhibitors, mineralocorti-
coid receptor antagonist, β-blockers, statins, aspirin, nonsteroidal 
anti-inflammatory drugs). Differences in patient characteristics 
between groups were assessed using standardized differences 
before and after propensity score matching. Figure S1 shows 
the distribution of the propensity score in the 2 groups pre- and 
postmatching. The associations between SOT status and clinical 
outcomes were assessed using binomial generalized linear models 
(log-binomial model) with reporting of relative risks.
Differences in other variables, such as symptoms prior to ICU 
admission, receipt of immunosuppressive medications, vital signs, 
laboratory results, and receipt of invasive mechanical ventilation on 
ICU admission, as well as treatments and outcomes, were assessed 
by Student's t test or Mann-Whitney U test for continuous variables 
and chi-square-test (or Fisher's exact test) for categorical variables.
We conducted several sensitivity analyses to evaluate the ro-
bustness of our main findings. We separately analyzed kidney trans-
plant recipients and their controls in the propensity matched cohort. 
In addition, we repeated all analyses in the entire cohort. In these 
analyses, we performed log-binomial unadjusted and multivariable 
regression, where we adjusted for the same variables included in 
the calculation of the propensity score. Moreover, we repeated all 
analyses after creating a different propensity score-matched cohort 
by 1-to-1 nearest neighbor matching without replacement.
A total of 5% of the data were missing. We did not impute miss-
ing values because of the relatively low proportion of missingness. 
Reported P values are 2 sided and reported as significant at <.05 
for all analyses. All analyses were conducted using STATA/MP 
Version 13.1 (STATA Corporation, College Station, TX). The study 
was approved by the Institutional Review Board of the University of 
Tennessee Health Science Center (20-07289-XP).
3  |  RESULTS
3.1  |  Baseline characteristics
A total of 4512 critically ill patients with COVID-19 were identified as the 
source population. The flow chart for the cohort is shown in Figure 1. 
We excluded patients who were admitted to ICUs after May 8, 2020, 
to allow 28 days follow-up (n = 189). We also excluded patients missing 
data on death (n = 15) or SOT status (n = 3) and patients with end-stage 
renal disease (n = 152), which resulted in a study population of 4153 
patients, including 105 SOT patients. Our propensity score-matched 
cohort included 386 patients (98 SOT and 288 non-SOT patients). The 
distribution of the 98 SOT patients included 67 kidney, 13 liver, 13 heart, 
4 lung, and 1 pancreas transplant recipient. Among the 67 kidney trans-
plant patients, there was 1 combined kidney/liver, 4 combined kidney/
heart, and 3 combined kidney/pancreas transplant patients.
In the overall cohort of 4153 patients (before applying the propen-
sity matching), the median age was 62 years (IQR, 52-71 years), 64% 
were male, and 30% were black (Table S3). The SOT patients were 
younger are were more likely to be male, black, and to have diabetes 
mellitus, hypertension, coronary artery disease, congestive heart fail-
ure, chronic kidney disease, and chronic liver disease. SOT patients 
were also more likely to be receiving a beta blocker, statin, or aspirin 
prior to hospital admission as compared to non-SOT patients (Table S3).
In the propensity score matched cohort, SOT and non-SOT 
patients had similar baseline characteristics (Table 1). The median 
age was 60 years, 72% were male, and 41% were black (Table 1). 
The SOT and non-SOT groups were well-balanced, as evidenced 
by the small standardized differences between groups (Table 1). 
Immunosuppressive medications were present almost exclusively in 
SOT patients prior to admission (Table 1).
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3.2  |  Symptoms prior to admission and clinical 
characteristics on the day of ICU admission
Table 2 shows symptoms, vital signs, laboratory values, and data 
on receipt of invasive mechanical ventilation on ICU admission. 
SOT patients experienced nasal congestion and diarrhea more 
frequently as symptoms of COVID-19 infection, and had longer 
time elapsed between the start of symptoms and ICU admis-
sion, than non-SOT patients; other symptoms were similar be-
tween the groups. SOT patients had lower temperature, higher 
systolic blood pressure, lower white blood cell count, lower ab-
solute lymphocyte count, and higher serum ferritin compared 
to non-SOT patients in the propensity score matched cohort. 
Interestingly, the C-reactive protein was similar between the 2 
groups (Table 2).
3.3  |  Medications in the 14 days following 
ICU admission
Table 3 describes the treatments received in the 14 days after ICU 
admission. A higher proportion of SOT patients received corticoster-
oids (SOT: 65% vs. non-SOT: 38%, P < .001) and a lower proportion 
received nonsteroidal anti-inflammatory drugs (SOT: 0% vs non-
SOT: 5%, P = .03) in the propensity score matched cohort. The use 
of other medications, including hydroxychloroquine, azithromycin, 
remdesivir, tocilizumab, and anticoagulants, was similar between 
groups (Table 3).
3.4  |  Clinical outcomes and organ support
Tables 4 and 5 and Figure S2 show the clinical outcomes and organ 
support requirements in SOT and non-SOT patients. Death within 
28 days of ICU admission was similar in SOT and non-SOT patients 
(40% and 43%, respectively; relative risk [RR] 0.92; 95% confidence 
interval [CI]: 0.70-1.22). Other outcomes and requirement for organ 
support were also similar between groups, including receipt of me-
chanical ventilation, development of acute respiratory distress syn-
drome, receipt of ECMO and receipt of vasopressors (Tables 4-5 and 
Figure S2). There was a trend toward higher risk of AKI requiring 
RRT in SOT vs. non-SOT patients (37% vs. 27%; RR [95% CI]: 1.34 
[0.97-1.85]). Figure S3 shows the clinical outcomes and organ sup-
port requirements in SOT and non-SOT patients using the 1:1 PS 
matched cohort as a sensitivity analysis. Death within 28 days of 
ICU admission and requirement for organ support were also similar 
between groups (Figure S3). In addition, clinical outcomes, and organ 
support requirements were similar between kidney transplant pa-
tients versus nontransplant propensity score (PS) matched controls 
(Tables S4 and Figures S4).
3.5  |  Clinical outcomes and organ support 
requirements in the entire cohort
Table S5 and Figure S5 shows the clinical outcomes and organ sup-
port requirement in SOT and non-SOT patients in the entire cohort 
(n = 4,153). Similar to the propensity score matched cohort, death 
F I G U R E  1   Flow chart of patient selection. COVID-19, coronavirus disease 2019; SOT, solid organ transplantation; ICU, intensive care 
unit; ESRD, end-stage renal disease










(n = 98) St Diff
Demographics
Age (years) median (IQR) 60 (51-70) 61 (51-70) 58 (52-69) −0.004
Sex (male) – no. (%) 277 (72) 205 (71) 72 (73) −0.051
Race – no. (%) 0.078
White 128 (33) 99 (34) 29 (30)
Black 159 (41) 116 (40) 43 (44)
Asian/other 99 (26) 73 (25) 26 (27)
Ethnicity – no. (%) 0.036
Hispanic 68 (18) 48 (17) 20 (20)
Non-Hispanic 287 (74) 221 (77) 66 (67)
Unknown 31 (8) 19 (7) 12 (12)
Body mass index (kg/m2), 
mediana (IQR)
29 (25-33) 29 (26-34) 29 (25-33) −0.103
Coexisting conditions – no. (%)
Diabetes mellitus 253 (66) 189 (66) 64 (65) −0.007
Hypertension 317 (82) 235 (82) 82 (84) 0.055
Coronary artery disease 104 (27) 78 (27) 26 (27) −0.012
Congestive heart failure 71 (18) 51 (18) 20 (20) 0.069
Atrial fibrillation or atrial 
flutter
48 (12) 35 (12) 13 (13) 0.033
Chronic obstructive 
pulmonary disease
21 (5) 15 (5) 6 (6) 0.039
Asthma 23 (6) 17 (6) 6 (6) 0.009
Other pulmonary disease 50 (13) 37 (13) 13 (13) 0.012
Smoking statusb −0.029
Nonsmoker 240 (62) 180 (63) 60 (61)
Former smoker 109 (28) 78 (27) 31 (32)
Current smoker 8 (2) 8 (3) 0 (0)
Unknown 29 (8) 22 (8) 7 (7)
Chronic kidney disease 198 (51) 143 (50) 55 (56) 0.129
Chronic liver disease 35 (9) 23 (8) 12 (12) 0.141
HIV/AIDS 10 (3) 7 (2) 3 (3) 0.038
Active malignancy 25 (6) 18 (6) 7 (7) 0.036
Home medications – no. (%)
ACE-I 75 (19) 59 (20) 16 (16) −0.107
ARB 80 (21) 59 (20) 21 (21) 0.023
Mineralocorticoid receptor 
antagonist
9 (2) 7 (2) 2 (2) −0.026
Beta blocker 223 (58) 162 (56) 61 (62) 0.122
Statin 229 (59) 171 (59) 58 (59) −0.004
NSAID 2 (1) 1 (0) 1 (1) 0.081
Aspirin 186 (48) 138 (48) 48 (49) 0.021
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor 
blocker; HIV/AIDS, human immunodeficiency virus infection/acquired immune deficiency 
syndrome; IQR, interquartile range; NSAID, nonsteroidal anti-inflammatory drug; SOT, solid organ 
transplant; St Diff: standardized differences.
TA B L E  1   Baseline characteristics of 
solid organ transplant and nontransplant 
patients after propensity score matching
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TA B L E  2   Clinical characteristics on the day of ICU admission in solid organ transplant patients and nontransplant patients in the 
propensity score matched cohort
Clinical characteristics Cohort (N = 386)
Non-SOT 
(N = 288) SOT (N = 98)
P 
value
Symptoms prior to ICU admission – no. (%)
Cough 269 (70) 196 (68) 73 (74) .23
Sputum production 46 (12) 32 (11) 14 (14) .40
Hemoptysis 7 (2) 6 (2) 1 (1) .50
Sore throat 35 (9) 27 (9) 8 (8) .72
Nasal congestion 31 (8) 18 (6) 13 (13) .03
Headache 33 (9) 24 (8) 9 (9) .80
Fever 236 (61) 177 (61) 59 (60) .83
Chills 83 (22) 60 (21) 23 (23) .58
Dyspnea 272 (70) 198 (69) 74 (76) .21
Nausea or vomiting 76 (20) 59 (20) 17 (17) .50
Diarrhea 92 (24) 58 (20) 34 (35) <.01
Myalgia or arthralgia 97 (25) 70 (24) 27 (28) .52
Confusion or altered mental status 46 (12) 35 (12) 11 (11) .81
Fatigue or malaise 143 (37) 111 (39) 32 (33) .30
Days from symptom onset to ICU admission 
median (IQR)a 
7 (4-10) 7 (4-10) 7 (6-11) <.01
Days from symptom onset to hospital admission 
median (IQR)b 
5 (3-8) 5 (3-7) 6 (3-8) .04
Immunosuppressive medications 30 days prior to ICU admission – no. (%)
Corticosteroidsc  29 (8) 14 (5) 15 (15) <.01
Calcineurin inhibitor 82 (21) 1 (0) 81 (83) <.01
Mycophenolate mofetil 69 (18) 2 (1) 67 (68) <.01
Azathioprine 3 (1) 3 (1) 0 (0) .31
Rituximab 0 (0) 0 (0) 0 (0) N/A
Other major ISU therapy 20 (5) 7 (2) 13 (13) <.01
Vital signs on the day of ICU admission – median (IQR)
Temperature – ⁰Cd  37.8 (37.1-38.6) 37.9 (37.2-38.8) 37.4 (36.9-38.2) <.01
Lowest systolic blood pressure – mm Hg 99 (88-114) 98 (86-112) 105 (92-117) .03
Highest heart rate – beats per min 103 (90-118) 103 (91-118) 101 (88-116) .32
Laboratory findings on the day of ICU admission – median (IQR)
White blood cell count – per mmd  7.5 (5.5-10.5) 7.9 (5.6-11.2) 6.6 (4.9-8.5) <.01
Lymphocyte percentage – per mmf  0.70 (0.45-1.05) 0.79 (0.52-1.15) 0.50 (0.30-0.81) <.01
Hemoglobin – g/dlg  11.8 (10.0-13.8) 11.7 (9.9-13.6) 11.9 (10.6-13.6) .47
Serum creatinine – mg/dlh  1.6 (1.0-2.8) 1.5 (1.0-2.9) 1.7 (1.0-2.7) .42
C-reactive protein – mg/Lj  156 (88-223) 159 (91-224) 143 (84-208) .49
Serum albumin – g/dlk  3.3 (2.8-3.6) 3.3 (2.8-3.6) 3.2 (2.9-3.6) .55
D-dimer - ng/mll  1,254 (620-2,975) 1,332 (610-3,402) 1,140 (640-2,390) .60
Interleukin-6 - pg/mlm  51 (15-184) 68 (13-195) 37 (15-84) .61
Serum ferritin – ng/mln  1,132 (541-2,112) 998 (450-1,983) 1,429 (657-2,957) .03
Type of ventilation - no. (%):
Invasive mechanical ventilation 226 (59) 171 (59) 55 (56) .34
BIPAP or CPAP 7 (2) 6 (2) 1 (1)
High-flow nasal cannula or nonrebreather mask 88 (23) 68 (24) 20 (20)
(Continues)
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within 28 days, mechanical ventilation, ECMO requirement, devel-
opment of ARDS, secondary infection, thromboembolic events, and 
requirement for vasopressors were all similar between groups. The 
risk of AKI requiring RRT was higher in SOT patients compared to 
non-SOT patients (36% in SOT vs. 19% in non-SOT, RR unadjusted model 
[95% CI]: 1.89 [1.46-2.46], RR adjusted model [95% CI]: 1.43 [1.09-1.87]) 
(Table S5 and Figure S5).
4  |  DISCUSSION
We used data from a large, nationally representative, multicenter 
cohort study of critically ill adults with COVID-19 to compare out-
comes of SOT patients with non-SOT patients. We present 3 major 
findings. First, 28-day mortality in SOT patients was similar to non-
SOT patients. Second, there was no difference between groups in 
the duration of ICU length of stay, risk of ARDS, secondary infec-
tion, thromboembolic events, vasopressor use, or receipt or duration 
of invasive mechanical ventilation. Finally, SOT patients had a trend 
toward higher rates of AKI requiring RRT. To the best of our knowl-
edge, this is the first study assessing outcomes of COVID-19 infec-
tion in SOT patients using a control group of nontransplant patients 
as comparator in ICU patients.
Our study suggests that SOT status is not associated with a higher 
risk of mortality in critically ill patients with COVID-19. Our observed 
mortality rate of 40% in SOT patients and 43% in the non-SOT group 
is lower than the 62% mortality rate reported among critically ill pa-
tients with COVID-19 in Wuhan3 and the 50% mortality rate reported 
in the Seattle region.5 It was, however, higher than other cohorts from 
Italy (26%) 7 and New York City (15%-21%).4,6 These comparisons are 
limited by different risk profile of patients, ICU admission criteria, and 
follow-up. Similarly, the case fatality rate of COVID-19 in hospitalized 
SOT patients reportedly varies between 10%-33%,8,9,13-16 but among 
critically ill SOT patients it may be as high as 50%.8 Previous expe-
rience with respiratory viruses suggests a higher mortality in SOT 
patients compared to non-SOT patients, yet we report no difference 
in the 28-day mortality risk in our cohort. One potential explanation 
is that there was a higher use of corticosteroid treatment in SOT 
patients compared to non-SOT patients. The recent “Randomised 
Evaluation of COVid-19 thERapY (RECOVERY)” study indicated that 
dexamethasone therapy reduces death by up to one third in hospital-
ized patients with severe respiratory complications of COVID-19.25 
We hypothesize that immunosuppressive medications may have mit-
igated proinflammatory cytokine activation in SOT patients, which 
might result in lower risk of developing cytokine release syndrome. 
Since the earliest reports of COVID-19 infection, cytokine release 
syndrome has been identified as a primary contributor to the patho-
physiology of severe COVID-19 infection, including ARDS and organ 
dysfunction.26,27 Coronavirus infection results in the activation of 
monocyte, macrophage, and dendritic cells, which in turn release in-
terleukin-6 (IL-6) and other cytokines, contributing to the clinical man-
ifestations of severe infection. Ensuing endothelial injury can lead to 
multiorgan involvement. However, in our dataset C-reactive protein 
levels and IL-6 levels were similar between the 2 groups despite the 
immunosuppression, which does not support our hypothesis. In addi-
tion, serum ferritin level was higher in SOT patients. Further studies 
are needed to clarify the potential role of cytokine release syndrome 
in this population.
SOT patients had a nonsignificant trend toward a more than 30% 
higher risk of AKI requiring RRT compared to their non-SOT counter-
parts similar to what was reported in a recent single-center study.23 
Initial reports of AKI in hospitalized patients with COVID-19 varied 
from 15% to 50%9,13,18,19 and has been reported to be as high as 
90% among mechanically ventilated patients.28 A multicenter cohort 
Clinical characteristics Cohort (N = 386)
Non-SOT 
(N = 288) SOT (N = 98)
P 
value
None of the above 65 (17) 43 (15) 22 (22)
Note: All other variables had no missing data.
Abbreviations: BiPAP, bilevel positive airway pressure ventilation; IQR, interquartile range; ISU, immunosuppressive; N/A, not applicable; CPAP, 
continuous positive airway pressure ventilation; SOT, solid organ transplant.
aData regarding days from symptom onset to ICU admission were missing for total 4 patients (1%), 1 SOT patient and 3 non-SOT patients. 
bData regarding days from symptom onset to hospital admission were missing for total 14 patients (3.6%), 3 SOT patient and 11 non-SOT patients. 
cCorticosteroids: >10 mg prednisone/day (or equivalent). 
dData regarding temperature were missing for total 2 patients (0.5%), 1 SOT patient and 1 non-SOT patients.  
eData regarding white-cell count were missing for total 16 patients (4%), 3 SOT patient and 13 non-SOT patients.  
fData regarding lymphocyte percentage were missing for total 76 patients (19.6%), 18 SOT patient and 58 non-SOT patients.  
gData regarding hemoglobin were missing for total 16 patients (4%), 3 SOT patient and 13 non-SOT patients.  
hData regarding serum creatinine were missing for total 13 patients (3.4%), 3 SOT patient and 10 non-SOT patients.  
iData regarding estimated glomerular filtration rate were missing for total 13 patients (3.4%), 3 SOT patient and 10 non-SOT patients.  
jData regarding C-reactive protein were missing for total 150 patients (38.8%), 40 SOT patient and 110 non-SOT patients.  
kData regarding serum albumin were missing for total 63 patients (16.3%), 14 SOT patient and 49 non-SOT patients.  
lData regarding D-dimer were missing for total 194 patients (50%), 40 SOT patient and 154 non-SOT patients.  
mData regarding interleukin-6 were missing for total 304 patients (79%), 75 SOT patient and 229 non-SOT patients.  
nData regarding serum ferritin were missing for total 163 patients (42%), 34 SOT patient and 129 non-SOT patients.  
TA B L E  2   Continued







(N = 98) P value
Antibiotics/antivirals – no. (%)
Chloroquine 3 (1) 1 (0) 2 (2) .10
Hydroxychloroquine 258 (67) 196 (68) 62 (63) .38
Azithromycin 199 (52) 150 (52) 49 (50) .72
Hydroxychloroquine and 
azithromycin
307 (80) 233 (81) 74 (76) .25
Remdesivir 26 (7) 20 (7) 6 (6) .78
Ribavirin 1 (0) 1 (0) 0 (0) .56
Lopinavir/ritonavir (Kaletra) 14 (4) 11 (4) 3 (3) .73
Therapeutic anticoagulation – 
no. (%)a 
Any 176 (46) 130 (45) 46 (47) .78
Heparin drip 132 (34) 96 (33) 36 (37) .54
Enoxaparin 41 (11) 35 (12) 6 (6) .09
Bivalirudin 4 (1) 1 (0) 3 (3) .02
Argatroban 1 (0) 1 (0) 0 (0) .56
Anti-inflammatory medications 
– no. (%)
Corticosteroids 173 (45) 109 (38) 64 (65) <.01
NSAIDs 13 (3) 13 (5) 0 (0) .03
Aspirin 128 (33) 94 (33) 34 (35) .71
Statin 132 (34) 92 (32) 40 (41) .11
Tocilizumab 70 (18) 47 (16) 23 (23) .11
Other interleukin-6 
inhibitor or interleukin-6 
receptor inhibitor
2 (1) 1 (0) 1 (1) .42
Vitamin C 32 (8) 28 (10) 4 (4) .08
Other medications – no. (%)
Convalescent plasma 12 (3) 7 (2) 5 (5) .19
ACE-I 12 (3) 10 (3) 2 (2) .48
ARB 14 (4) 11 (4) 3 (3) .73
Tissue plasminogen activator 5 (1) 4 (1) 1 (1) .78
Specific interventions for 
hypoxemia – no. (%)
Neuromuscular blockade 142 (37) 105 (36) 37 (38) .82
Inhaled epoprostenol 18 (5) 13 (5) 5 (5) .81
Inhaled nitric oxide (iNO) 22 (6) 14 (5) 8 (8) .22
Prone position 126 (33) 92 (32) 34 (35) .62
Enrolled in a clinical trial – 
no. (%)b 
75 (19) 55 (19) 20 (20) .79
Note: Each of the above interventions was assessed during the 14 days following ICU admission. 
All other variables had no missing data.
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor 
blocker; ICU, intensive care unit; N/A: not applicable; NSAIDs, nonsteroidal anti-inflammatory 
drugs; SOT, solid organ transplant.
aData on therapeutic anticoagulation were missing for 1 non-SOT patient (0.3%). 
bData on enrollment in a clinical trial were missing for 1 non-SOT patient (0.3%). 
TA B L E  3   Treatments in the first 
14 days after intensive care unit admission 
of nontransplant patients and solid organ 
transplant patients in the propensity score 
matched cohort





(n = 98) P value*
Death within 28 days, n (%) 124 (43) 39 (40) .57
Cause of death, n (%)** .50
ARDS/respiratory failure 39 (29) 13 (30)
Heart failure 5 (4) 1 (2)
Septic shock 16 (12) 10 (23)
Kidney failure 42 (32) 13 (30)
Liver failure 10 (8) 2 (5)
Other 21 (16) 4 (9)
Days of ICU stay, median (IQR) 11 (5-21) 11 (7-19) .42
Mechanical ventilation (days 1-14)
Received mechanical ventilation, n (%) 223 (77) 78 (80) .66
Days of mechanical ventilation, median (IQR) 11 (6-14) 9 (6-13) .18
ECMO (days 1-14)
Received ECMO, n (%) 9 (3) 1 (1) .26
Days of ECMO, median (IQR) 8 (5-9) 14 (14-14) .16
Acute RRT (days 1-14)
Received acute RRT, n (%) 79 (27) 36 (37) .08
Days of acute RRT, median (IQR) 7 (3-10) 6 (3-9) .76
ARDS (days 1-14), n (%) 205 (71) 73 (74) .56
New infection (days 1-14), n (%) 99 (34) 24 (24) .07
New thromboembolic event (days 1-14), n (%) 23 (8) 9 (9) .71
Vasopressor (days 1-14)
Received vasopressor, n (%) 201 (70) 62 (63) .23
Days on vasopressor, median (IQR) 5 (3-9) 5 (3-9) .52
Abbreviations: ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane 
oxygenation; ICU, intensive care unit; IQR, interquartile range; RRT, renal replacement therapy; 
SOT, solid organ transplantation.
*P values for continuous variables with median (IQR) are result of Mann-Whitney test and 
categorical variables are chi-square test.
**Patients could have had more than one cause of death.
Primary outcomes Relative risk




Death within 28 days, n (%) 0.92 0.70-1.22 .58
Mechanical ventilation (days 
1-14)
1.03 0.91-1.16 .65
ECMO (days 1-14) 0.33 0.04-2.54 .29
Acute RRT (days 1-14) 1.34 0.97-1.85 .07
ARDS (days 1-14), n (%) 1.04 0.91-1.20 .55
New infection (days 1-14), n (%) 0.71 0.48-1.04 .08
New thromboembolic event 
(days 1-14), n (%)
1.15 0.55-2.40 .71
Vasopressor (days 1-14) 0.91 0.77-1.07 .26
Abbreviations: ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane 
oxygenation; RRT, renal replacement therapy; SOT, solid organ transplant.
TA B L E  5   Relative risk of clinical 
outcomes and organ support in 
nontransplant patients and solid organ 
transplant patients in the propensity 
score matched cohort using binomial 
generalized linear model (log-binomial 
model) (SOT versus non-SOT [reference] 
patients)
TA B L E  4   Clinical outcomes and organ 
support requirement in nontransplant 
patients and solid organ transplant 
patients in the propensity score matched 
cohort
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study of more than 5000 hospitalized patients from New York City 
reported a 36% incidence of AKI, with 14% of those with AKI (5% of 
all patients) requiring RRT.28 In another large study of 3235 hospital-
ized patients from New York City with 815 ICU patients, the need 
for RRT was present in 34% of ICU patients,29 which is similar to 
our reported results. Similarly, the reported incidence of AKI in SOT 
patients varies according to the type of organ transplant and sever-
ity of disease.30 In the first report of US kidney transplant patients, 
40% (6/15) of the patients had AKI and 2 patients required RRT.15 
The mechanisms of AKI in transplant patients are multifactorial. 
Virus particles can directly infect the renal tubular epithelium and 
podocytes through an angiotensin-converting enzyme 2 (ACE2)-
dependent pathway and cause mitochondrial dysfunction and acute 
tubular necrosis. Endothelial dysfunction due to endothelial injury 
increases the risk of microthrombi and contributes to AKI.11 In ad-
dition to AKI associated with ARDS and critical illness, use of cal-
cineurin inhibitors as the predominant immunosuppression could 
increase the risk of endothelial injury in these patients; especially in 
the setting of higher rate of diarrhea.
There was a significant difference in symptoms at presentation 
between SOT and non-SOT patients. Fever and cough were the most 
common symptoms in both groups, consistent with previous descrip-
tion of COVID-19 symptoms. Interestingly, SOT patients presented 
with more nasal congestion and diarrhea compared to non-SOT pa-
tients. Although other case reports and cohorts of SOT patients pre-
senting with gastrointestinal symptoms exist,20,31 this has not been 
consistently shown in other studies, where the presenting symptoms 
in SOT patients were similar to the general population.18,22,32 Our find-
ings are important, as diarrhea in SOT patients is common and can be 
multifactorial, related to medications or other viral infections. Given 
the myriad of clinical manifestations that have been described in pa-
tients with COVID-19, the index of suspicion for COVID-19 should be 
high in SOT patients who present with gastrointestinal symptoms.
Our study has several strengths. First, we included patients 
from geographically diverse sites from across the United States, 
thereby maximizing generalizability. Second, we used propensity 
score matching to create comparable groups to assess the risk of 
SOT status with several clinically relevant outcomes. Third, all data 
were captured by manual chart review, which allowed us to include 
detailed and reliable data on both clinical characteristics and out-
comes. Fourth, to the best of our knowledge our study included the 
highest number of SOT ICU patients from the United States. Finally, 
all patients had follow-up until the first of hospital discharge, death, 
or at least 28 hospital days.
Our study also has its limitations. First, the transplant vintage 
of SOT patients was not available in this dataset and hence, the 
effect of duration of immunosuppression and time since transplan-
tation on outcomes cannot be determined. Second, although we 
captured data on the use of immunosuppressive medications prior 
to hospital admission, we did not capture data on their use follow-
ing ICU admission. Thus, our study does not address the import-
ant question of whether, and how, immunosuppression should be 
decreased in critically ill patients with COVID-19. Third, our study 
collected data in the first 14 days of ICU stay, so our study does not 
address the potential association with data after first 2 weeks of 
ICU stay. Finally, these observations are restricted to ICU patients 
and may not be applicable for non-ICU or ambulatory SOT patients.
5  |  CONCLUSION
In conclusion, SOT patients with critical illness due to COVID-19 in-
fection have a similar risk of death, ARDS, and requirement for organ 
support as non-SOT patients. Further studies are needed to assess 
the effect of specific immunosuppression and other therapeutic 
regimens on clinical outcomes.
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